Brain-membrane cholesterol in Alzheimer's disease

Journal of Nutrition, Health and Aging

Volumn 7, Issue 1, 2003, Pages 18-23

  Eckert, Gunter P ^a   Kirsch, C ^a   Muller W E ^a  

^a Biocenter N260   (Germany)

Author keywords

Aging; Alzheimer; Amyloid; Brain; Cholesterol; Elderly; Membrane; Nutrition

Indexed keywords

1,6 DIPHENYL 1,3,5 HEXATRIENE; AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; CHOLESTEROL; CYCLODEXTRIN; HYPOCHOLESTEROLEMIC AGENT; MEVINOLIN; PHOSPHOLIPID; TAU PROTEIN;

ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL TISSUE; ANISOTROPY; ARTICLE; BRAIN MEMBRANE; CELL MEMBRANE; CHOLESTEROL SYNTHESIS; CONTROLLED STUDY; EVIDENCE BASED MEDICINE; FLUORESCENCE; HUMAN; HUMAN TISSUE; MOUSE; NEUROTOXICITY; NONHUMAN; PATHOGENESIS; PHOSPHOLIPID BILAYER; PRIORITY JOURNAL; PROTECTION; PROTEIN BINDING; PROTEIN SYNTHESIS; PUBLICATION; X RAY DIFFRACTION;

ANIMALIA;

EID: 0037281233     PISSN: 12797707     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (75)

1. Verbeek M. M., Ruiter D. J., De Waal R. M. W., The role of amyloid in the pathogenesis of Alzheimer's disease, Biol. Chem., 1997, 378: 937-950.
2. Sinha S., Lieberburg I., Cellular mechanisms of beta-amyloid production and secretion, Proc. Natl. Acad. Sci. U. S. A., 1999, 96: 11049-11053.
3. Haass C., Schlossmacher M. G., Hung A. Y., Vigo-Pelfrey C., Mellon A., Ostaszewski B. L., Lieberburg I., Koo E. H., Schenk D., Teplow D. B., Amyloid beta-peptide is produced by cultured cells during normal metabolism, Nature, 1992, 359: 322-325.
4. Hussain I., Powell D., Howlett D. R., Tew D. G., Meek T. D., Chapman C., Gloger I. S., Murphy K. E., Southan C. D., Ryan D. M., Smith T. S., Simmons D. L., Walsh F. S., Dingwall C., Christie G., Identification of a novel aspartic protease (Asp 2) as beta-secretase, Mol. Cell Neurosci., 1999, 14: 419-427.
5. Sinha S., Anderson J. P., Barbour R., Basi G. S., Caccavello R., Davis D., Doan M., Dovey H. F., Frigon N., Hong J., Jacobson-Croak K., Jewett N., Keim P., Knops J., Lieberburg I., Power M., Tan H., Tatsuno G., Tung J., Schenk D., Seubert P., Suomensaari S. M., Wang S., Walker D., John V., Purification and cloning of amyloid precursor protein beta-secretase from human brain, Nature, 1999, 402: 537-540.
6. Yan R., Bienkowski M. J., Shuck M. E., Miao H., Tory M. C., Pauley A. M., Brashier J. R., Stratman N. C., Mathews W. R., Buhl A. E., Carter D. B., Tomasselli A. G., Parodi L. A., Heinrikson R. L., Gurney M. E., Membrane-anchored aspartyl protease with Alzheimer's disease beta-secretase activity, Nature, 1999, 402: 533-537.
7. Iversen L. L., Mortishire Smith R. J., Pollack S. J., Shearman M. S., The toxicity in vitro of beta-amyloid protein, Biochem. J., 1995, 311: 1-16.
8. Yankner B. A., Duffy L. K., Kirschner D. A., Neurotrophic and neurotoxic effects of amyloid - beta protein: Reversal by tachykinin neuropeptides, Science, 1990, 250: 279-282.
9. Pike C. J., Walencewicz A. J., Glabe C. G., Cotman C. W., In vitro aging of betaamyloid protein causes peptide aggregation and neurotoxicity, Brain Res., 1991, 563: 311-314.
10. Hartmann H., Eckert A., Müller W. E., Beta-Amyloid protein amplifies calcium signalling in central neurons from the adult mouse, Biochem. Biophys. Res. Commun., 1993, 194: 1216-1220.
11. Müller W. E., Hartmann H., Eckert G. P., Eckert A., Eisert S., Cholesterol affects neuronal calcium signalling. A possible link between apolipoprotein polymorphism, b - amyloid neurotoxicity, and neurodegeneration in Alzheimer's disease, Nutr. Metab. Card. Dis., 1997, 7: 210-216.
12. Butterfield D. A., Martin L., Carney J. M., Hensley K., A beta (25-35) peptide displays H2O2-like reactivity towards aqueous Fe2+, nitroxide spin probes, and synaptosomal membrane proteins, Life Sci., 1996, 58: 217-228.
13. Cafe C., Bertorelli L., Angeretti N., Lucca E., Forloni G., Marzatico, F., Oxidative stress after acute and chronic application of beta - amyloid fragment 25-35 in cortical cultures, Neurosci. Lett., 1996, 203: 61-65.
14. Estus S., Tucker H. M., Van Rooyen C., Wright S., Brigham E. F., Wogulis M., Rydel R. E., Aggregated amyloid-beta protein induces cortical neuronal apoptosis and concomitant "apoptotic" pattern of gene induction, J. Neurosci., 1997, 17: 7736-7745.
15. Yuan J., Yankner B. A., Apoptosis in the nervous system, Nature, 2000, 407: 802-809.
16. Behl C., Davis J. B., Klier F. G., Schubert D., Amyloid beta pepfide induces necrosis rather than apoptosis, Brain Res., 1994, 645: 253-264.
17. Kanfer J. N., Sorrentino G., Sitar D. S., Amyloid beta peptide membrane perturbation is the basis for its biological effects, Neurochem. Res., 1999, 24: 1621-1630.
18. Frears E. R., Stephens D. J., Walters C. E., Davies H., Austen B. M., The role of cholesterol in the biosynthesis of beta-amyloid, Neuroreport, 1999, 10: 1699-1705.
19. Wood W. G., Schroeder F., Avdulov N. A., Chochina S. V., Igbavboa U., Recent advances in brain cholesterol dynamics: transport, domains, and Alzheimer's disease, Lipids, 1999, 34: 225-234.
20. Mori T., Paris D., Town T., Rojiani A. M., Sparks D. L., Delledonne A., Crawford F., Abdullah L. I., Humphrey J. A., Dickson D. W., Mullan M. J., Cholesterol accumulates in senile plaques of Alzheimer disease patients and in transgenic APP(SW) mice, J. Neuropathol. Exp. Neurol., 2001, 60: 778-785.
21. Prasad M. R., Lovell M. A., Yatin M., Dhillon H., Markesbery W. R., Regional membrane phospholipid alterations in Alzheimer's disease, Neurochem. Res., 1998, 23: 81-88.
22. Wells K., Farooqui A. A., Liss L., Horrocks L. A., Neural membrane phospholipids in Alzheimer disease, Neurochem. Res., 1995, 20: 1329-1333.
23. Nitsch R. M., Blusztajn J. K., Pittas A.G., Slack B.E., Growdon J. H., Wurtman R. J., Evidence for a membrane defect in Alzheimer disease brain, Proc. Natl. Acad. Sci. U. S. A., 1992, 89: 1671-1675.
24. Dhillon H. S., Carbary T., Dose J., Dempsey R. J., Prasad M. R., Activation of phosphatidylinositol bisphosphate signal transduction pathway after experimental brain injury: a lipid study, Brain Res., 1995, 698: 100-106.
25. Katsura K., Rodriguez de Turco E. B., Folbergrova J., Bazan N. G., Siesjo B. K., Coupling among energy failure, loss of ion homeostasis, and phospholipase A2 and C activation during ischemia, J. Neurochem., 1993, 61: 1677-1684.
26. Jope R. S., Song L., Li X., Powers R., Impaired phosphoinositide hydrolysis in Alzheimer's disease brain, Neurobiol. Aging, 1994, 15: 221-226.
27. Gattaz W. F., Maras A., Cairns N. J., Levy R., Forstl H., Decreased phospholipase A2 activity in Alzheimer brains, Biol. Psychiatry, 1995, 37: 13-17.
28. Shimohama S., Fujimoto S., Matsushima H., Takenawa T., Taniguchi T., Perry G., Whitehouse P. J., Kimura, J., Alteration of phospholipase C-delta protein level and specific activity in Alzheimer's disease, J. Neurochem., 1995, 64: 2629-2634.
29. Young R. A., Talbot K., Gao Z., Trojanowski J. Q., Wolf B. A., Phospholipase pathway in Alzheimer's disease brains: decrease in Galphai in dorsolateral prefrontal cortex, Brain Res. Mol. Brain Res., 1999, 66: 188-190.
30. Guan Z., Wang Y., Cairns N. J., Lantos P. L., Dallner G., Sindelar P. J., Decrease and structural modifications of phosphatidylethanolamine plasmalogen in the brain with Alzheimer disease, J. Neuropathol. Exp. Neurol., 1999, 58: 740-747.
31. Pettegrew J. W., McClure R. J., Kafner J.N., Mason R. P., Panchalingam K., Klunk W. E. The Role of Membranes and Energetics in Alzheimer Disease. In: Alzheimer Disease. Raven Press, 1993.
32. Markesbery W. R., Carney J. M., Oxidative alterations in Alzheimer's disease, Brain Pathol., 1999, 9: 133-146.
33. Marcus D. L., Thomas C., Rodriguez C., Simberkoff K., Tsai J. S., Strafaci J. A., Freedman M. L., Increased peroxidation and reduced antioxidant enzyme activity in Alzheimer's disease, Exp. Neurol., 1998, 150: 40-44.
34. Hajimohammadreza I., Brammer M., Brain membrane fluidity and lipid peroxidation in Alzheimer's disease, Neurosci. Lett., 1990, 112: 333-337.
35. Christen Y., Oxidative stress and Alzheimer disease, Am. J. Clin. Nutr., 2000, 71: 621S-629S.
36. Palmer A. M., Burns M. A., Selective increase in lipid peroxidation in the inferior temporal cortex in Alzheimer's disease, Brain Res., 1994, 645: 338-342.
37. Bastiaanse E. M. L., Hoeld K. M., Van der Laarse A., The effect of membrane cholesterol content on ion transport processes in plasma membranes, Cardiovasc. Res., 1997, 33: 272-283.
38. Gimpl G., Burger K., Fahrenholz F., Cholesterol as modulator of receptor function, Biochemistry, 1997, 36: 10959-10974.
39. Ramjiawan B., Czubryt M. P., Gilchrist J. S. C., Pierce G. N., Nuclear membrane cholesterol can modulate nuclear nucleoside triphosphatase activity, J. Cell Biochem., 1996, 63: 442-452.
40. Svennerholm L., Gottfries C. G., Membrane lipids, selectively diminished in Alzheimer brains, suggest synapse loss as a primary event in early-onset form (type I) and demyelination in late-onset form (type II), J. Neurochem., 1994, 62: 1039-1047.
41. Mason R. P., Shoemaker W. J., Shajenko L., Chambers T. E., Herbette L. G., Evidence for changes in the Alzheimer's disease brain cortical membrane structure mediated by cholesterol, Neurobiol. Aging, 1992, 13: 413-419.
42. Mason R. P., Shoemaker W. J., Shajenko L., Herbette L. G., X-ray diffraction analysis of brain lipid membrane structure in Alzheimer's disease and beta-amyloid peptide interactions, Ann. N. Y. Acad. Sci., 1993, 695: 54-58.
43. Eckert G. P., Cairns N. J., Maras A., Gattaz W. F., Müller W. E., Cholesterol modulates the membrane-disordering effects of beta-amyloid peptides in the hippocampus: specific changes in Alzheimer's disease, Dement. Geriatr. Cogn. Disord., 2000, 11: 181-186.
44. Zubenko G. S., Hippocampal membrane alteration in Alzheimer's disease, Brain Res., 1986, 385: 115-121.
45. Scheuer K., Maras A., Gattaz W. F., Cairns N., Förstl H., Müller W. E., Cortical NMDA Receptor Properties and Membrane Fluidity are Altered in Alzheimer's Disease, Dementia, 1996, 7: 210-214.
46. Mecocci P., Cherubini A., Beal M. F., Cecchetti R., Chionne F., Polidori M. C., Romano G., Senin U., Altered mitochondrial membrane fluidity in AD brain, Neurosci. Lett., 1996, 207: 129-132.
47. Ginsberg L., Atack J. R., Rapoport S. I., Gershfeld N. L., Regional specificity of membrane instability in Alzheimer's disease brain, Brain Res., 1993, 615: 355-357.
48. Del Mar M., Villala, mez F., Structure of the Alzheimer beta-amyloid peptide (25-35) and its interaction with negatively charged phospholipid vesicles, Eur. J Biochem., 1999, 265: 744-753.
49. Terzi E., Holzemann G., Seelig J., Interaction of Alzheimer beta-amyloid peptide(1-40) with lipid membranes, Biochemistry, 1997, 36: 14845-14852.
50. Avdulov N. A., Chochina S. V., Igbavboa U., Warden C. S., Vassiliev A. V., Wood W. G., Lipid binding to amyloid beta-peptide aggregates: Preferential binding of cholesterol as compared with phosphatidylcholine and fatty acids, J. Neurochem., 1997, 69: 1746-1752.
51. Matsuzaki K., Horikiri C., Interactions of amyloid beta-peptide (1-40) with ganglioside-containing membranes, Biochemistry, 1999, 38: 4137-4142.
52. Yanagisawa K., Odaka A., Suzuki N., Ihara Y., GM1 ganglioside-bound amyloid beta-protein (A beta): a possible form of preamyloid in Alzheimer's disease, Nat. Med., 1995, 1: 1062-1066.
53. Mizuno T., Nakata M., Naiki H., Michikawa M., Wang R., Haass C., Yanagisawa K., Cholesterol-dependent generation of a seeding amyloid beta-protein in cell culture, J. Biol. Chem., 1999, 274: 15110-15114.
54. Seilheimer B., Bohrmann B., Bondolfi L., Mueller F., Stueber D., Doebeli H., The toxicity of the Alzheimer's beta-amyloid peptide correlates with a distinct fiber morphology, J. Struct. Biol., 1997, 119: 59-71.
55. Müller W. E., Koch S., Eckert A., Hartmann H., Scheuer K., 8-Amyloid peptide decreases membrane fluidity, Brain Res., 1995, 674: 133-136.
56. Müller W. E., Kirsch C., Eckert G. P., Membrane-disordering effects of beta-amyloid peptides, Biochem. Soc. Trans., 2001, 29: 617-623.
57. Müller W. E., Eckert G. P., Scheuer K., Cairns N. J., Maras A., Gattaz W. F., Effects of b-amyloid peptides on the fluidity of membranes from frontal and parietal lobes of human brain. High potencies of Ab1- 42 and Ab1-43, Amyloid., 1998, 5: 10-15.
58. Waschuk S., Elton E. A., Darabie A. A., Fraser P. E., McLaurin J., Cellular membrane composition defines Aβ-lipid interactions, J. Biol. Chem., 2001, in press:
59. Eckert G. P., Wood W. G., Müller W. E., Effects of Aging and Beta-Amyloid on the Fluidty of Brain Synaptic and Mitochondrial Membranes, J. Neural Transm., 2001, in press.
60. Kremer J. J., Pallitto M. M., Sklansky D. J., Murphy R. M., Correlation of betaamyloid aggregate size and hydrophobicity with decreased bilayer fluidity of model membranes, Biochemistry, 2000, 39: 10309-10318.
61. Mason R. P., Jacob R. F., Walter M. F., Mason P. E., Avdulov N. A., Chochina S. V., Igbavboa U., Wood W. G., Distribution and fluidizing action of soluble and aggregated amyloid beta-peptide in rat synaptic plasma membranes, J. Biol. Chem., 1999, 274: 18801-18807.
62. Chochina S. V., Avdulov N. A., Igbavboa U., Cleary J. P., O'Hare E. O., Wood W. G., Amyloid beta-peptide(1-40) increases neuronal membrane fluidity. Role of cholesterol and brain region, J. Lipid Res., 2001, 42: 1292-1297.
63. Zhou Y., Richardson J. S., Cholesterol protects PC12 cells from beta-amyloid induced calcium disordering and cytotoxicity, Neuroreport, 1996, 7: 2487-2490.
64. Hartmann H., Eckert A., Müller W. E., Apolipoprotein E and cholesterol affect neuronal calcium signalling: The possible relationship to beta-amyloid neurotoxicity, Biochem. Biophys. Res. Commun., 1994, 200: 1185-1192.
65. Kirsch C., Eckert G. P., Müller W. E., Cholesterol Modulates the Effects of Beta-Amyloid Peptide on Neuronal Membranes, 2001, submitted
66. Kaiser R. D., London E., Location of diphenylhexatriene (DPH) and its derivatives within membranes: comparison of different fluorescence quenching analyses of membrane depth, Biochemistry, 1998, 37: 8180-8190.
67. Eckert G. P., Kirsch C., Müller W. E., Differential effects of lovastatin treatment on brain cholesterol levels in normal and apoE-deficient mice, Neuroreport, 2001, 12: 883-887.
68. Wolozin B., Kellman W., Ruosseau P., Celesia G. G., Siegel G., Decreased prevalence of alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors, Arch. Neurol., 2000, 57: 1439-1443.
69. Fassbender K., Simons M., Bergmann C., Stroick M., Lutjohann D., Keller P., Runz H., Kuhl S., Bertsch T., von Bergmann K., Hennerici M., Beyreuther K., Hartmann T., Simvastatin strongly reduces levels of Alzheimer's disease beta-amyloid peptides Abeta 42 and Abeta 40 in vitro and in vivo, Proc. Natl. Acad. Sci. U. S. A, 2001, 98: 5856-5861.
70. Kojro E., Gimpl G., Lammich S., Marz W., Fahrenholz F., Low cholesterol stimulates the nonamyloidogenic pathway by its effect on the alpha -secretase ADAM 10, Proc. Natl. Acad. Sci. U. S. A, 2001, 98: 5815-5820.
71. Tokuda T., Tamaoka A., Matsuno S., Sakurai S., Shimada H., Morita H., Ikeda S., Plasma levels of amyloid beta proteins did not differ between subjects taking statins and those not taking statins, Ann. Neurol., 2001, 49: 546-547.
72. Bellosta S., Ferri N., Bernini F., Paoletti R., Corsini A., Non-lipid-related effects of statins, Ann. Med., 2000, 32: 164-176.
73. Fan Q. W., Yu W., Senda T., Yanagisawa K., Michikawa M., Cholesterol-dependent modulation of tau phosphorylation in cultured neurons, J. Neurochem., 2001, 76: 391-400.
74. Simons K., Ikonen E., How cells handle cholesterol, Science, 2000, 290: 1721-1726,
75. Dietschy J. M., Turley S. D., Cholesterol metabolism in the brain, Curr. Opin. Lipidol., 2001, 12: 105-112.